SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (9110)6/4/1998 10:09:00 AM
From: Frostman  Respond to of 23519
 
Yiwu, thanks! <<Vivus CEO Leland Wilson said the discrepancy between the two studies could be due to more detailed instructions on how to use the drug in the earlier study.>>

Does this response mean Leland is agreeing with the studies that trash the New England Journal of Medicine study? I would like to hear an analysis from Vivus staff medical people. That aside, if this is an attempt to define a problem, let's get onto the
solving-the-problem stage guys. Vivus at 6 1/2.



To: RealMuLan who wrote (9110)6/4/1998 3:29:00 PM
From: RealMuLan  Read Replies (2) | Respond to of 23519
 
It seems that a lot of shorts have been covered, and most of the longs who wanted to sell already did. At a such a depressing price, not many people want to initiate new short position. So with some good news, the price should go back somewhat. And with bad news, the price may even go lower, although not much, another 15% at most, just IMO.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News